MeSH tree: D12.776.543.750.750.360.100.500
As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing ...
Mar 13, 2026
0
16
Patients without diabetes who switched GLP-1 receptor agonist (GLP-1RA) drugs for overweight or obesity were more likely to stick with their treatment longer than those who didn't switch, according to a new study by UT Southwestern ...
Mar 10, 2026
0
12
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published ...
Mar 10, 2026
0
69
Researchers at Washington University School of Medicine in St. Louis have shown in a new study that GLP-1 medications may be effective at treating and preventing substance-use disorders across all major addictive substances ...
Mar 4, 2026
0
41
About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, obesity, or other conditions, according to a KFF Health Tracking poll. But many suffer from significant ...
Feb 27, 2026
0
12
Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years. Despite its clinical success, its precise molecular and cellular mechanisms are still ...
Feb 24, 2026
0
14
Popular weight-loss drugs, including Ozempic, Wegovy, Trulicity and Mounjaro, produced by independent pharmacy labs, sickened some 8,000 or more Marylanders a year by 2024. The Food and Drug Administration has announced that ...
Feb 24, 2026
0
17
For the first time, researchers show that tirzepatide—the active ingredient in the diabetes and weight-loss drug Mounjaro—reduces alcohol intake as well as relapse-like behaviors in rats and mice. The findings are considered ...
Feb 20, 2026
0
13
The popular diabetes and weight loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. ...
Feb 11, 2026
0
8
GLP-1 drugs have ushered in a new era in weight loss.
Feb 7, 2026
0
25
